| Literature DB >> 14567963 |
Dennis Wegener1, Christian Hildmann, Andreas Schwienhorst.
Abstract
Histone deacetylase (HDAC) inhibitors have an unprecedented potential to occupy a major position in the future market of anticancer agents. However, progress in the development of these new chemotherapeutics is largely dependent on the existence of bioassays well-suited for inhibitor screening. Herein, we summarize recent developments in HDAC assay technology and, particularly, discuss different assay types with respect to their suitability for high-throughput screening programs.Mesh:
Substances:
Year: 2003 PMID: 14567963 DOI: 10.1016/j.ymgme.2003.08.008
Source DB: PubMed Journal: Mol Genet Metab ISSN: 1096-7192 Impact factor: 4.797